Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies.

MLA

Pagan, Fernando L., et al. “Safety, Target Engagement, and Biomarker Effects of Bosutinib in Dementia with Lewy Bodies.” Alzheimer’s & Dementia (New York, N. Y.), vol. 8, no. 1, June 2022, p. e12296. EBSCOhost, https://doi.org/10.1002/trc2.12296.

APA

Pagan, F. L., Torres-Yaghi, Y., Hebron, M. L., Wilmarth, B., Turner, R. S., Matar, S., Ferrante, D., Ahn, J., & Moussa, C. (2022). Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies. Alzheimer’s & Dementia (New York, N. Y.), 8(1), e12296. https://doi.org/10.1002/trc2.12296

Chicago

Pagan, Fernando L, Yasar Torres-Yaghi, Michaeline L Hebron, Barbara Wilmarth, R Scott Turner, Sara Matar, Dalila Ferrante, Jaeil Ahn, and Charbel Moussa. 2022. “Safety, Target Engagement, and Biomarker Effects of Bosutinib in Dementia with Lewy Bodies.” Alzheimer’s & Dementia (New York, N. Y.) 8 (1): e12296. doi:10.1002/trc2.12296.